Navigation Links
Studies Show Efficacy and Safety of Alexion's Soliris in Broad,Population of PNH Patients

- Data presented at 12th Congress of European Hematology -

CHESHIRE, Conn., June 11, 2007 /PRNewswire-FirstCall/ -- Alexion Pharmaceuticals, Inc. today announced results from three analyses of Phase III studies examining Soliris(TM) (eculizumab) for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) at the 12th Congress of European Hematology, organized by The European Hematology Association (EHA) in Vienna. These presentations included:

"The Terminal Complement Inhibitor Eculizumab Reduces Thrombosis in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)," presented by Dr. Peter Hillmen of the General Infirmary at the University of Leeds, Leeds, UK.(1) (Abstract No. 0380)

"Safety and Efficacy of the Terminal Complement Inhibitor Eculizumab in Patients with Paroxysmal Nocturnal Hemoglobinuria: SHEPHERD Phase III Clinical Study Results," presented by Dr. Hubert Schrezenmeier of the University Hospital Ulm in Ulm, Germany.(2) (Abstract No. 0378)

"The Clinical Benefit of Eculizumab Is Demonstrable in all Subpopulations of Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) with Hemolysis," presented by Dr. Petra Muus of Radboud University, Nijmegen, Netherlands.(3) (Abstract No. 0379) Subpopulations were diverse and included patients with poor bone marrow function, smaller PNH clone sizes, low levels of hemolysis, less anemia, minimal pre-treatment transfusion requirements and those receiving steroids or erythropoietin.

Dr. Muus noted, "In published clinical trials, Soliris significantly reduced hemolysis in all PNH patients, which led to an improvement in anemia, patient functioning and quality of life, and fewer thrombotic events. Research presented this week at the Congress in Vienna described the impact of Soliris on multiple subgroups of PNH patients and showed that the effect of Soliris was maintained across all subpopulations including in those patients who had as
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
2. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
3. Studies of Drug Resistance May Lead to Individual Therapy for Rare Cancers
4. Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib Combination Studies
5. Insmed Inc. Welcomes Studies Linking IGFBP-3 to Prevention of Blindness in Premature Infants
6. Resveratrol Studies Suggest Broad Implications for SIRT1 Activation in Neurodegenerative Diseases of Aging Such as Alzheimers Disease
7. Publication on Pixantrone Preclinical Studies Demonstrates Reduced Cardiotoxicity Compared to Equiactive Doses of Doxorubicin and Mitoxantrone
8. Phosphagenics Announces Positive Proof of Concept Results from Studies Utilizing Companys Dermal Drug Delivery Technology
9. New Data from Multiple Studies Show Galvus Delivers Consistent and Robust Blood Sugar Control in Patients with Type 2 Diabetes
10. Eurands Zentase Effective in Treating Exocrine Pancreatic Insufficiency, Studies Show
11. Three Studies Suggest Abbotts Humira (adalimumab) May Improve Work Productivity in Patients with Rheumatoid Arthritis
Post Your Comments:
(Date:7/11/2014)... July 11, 2014 On ... down 0.52%, the Dow Jones Industrial Average finished the day ... 1,964.68, down 0.41%. The losses were broad based as eight ... S&P 500 Health Care Sector Index ended the day at ... the last one month. Investor-Edge has initiated coverage on the ...
(Date:7/11/2014)... , July 11, 2014 ... to Safety & Health Expo 2014 were ... move to London , ... attending exhibition.          ... http://photos.prnewswire.com/prnh/20140711/696892-a )      (Photo: ...
(Date:7/10/2014)... U.S. Department of Health and Human Services (HHS) has ... Medical Center Seidman Cancer Center totaling $4.7 million to ... for patients with complex cancer. Titled ... model developed at UH to enhance care for adult ... need for high health care utilization.  ...
Breaking Medicine Technology:Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 2Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 3Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 4UK's Flagship Health & Safety Event Has Successful Inaugural Year in London 2UK's Flagship Health & Safety Event Has Successful Inaugural Year in London 3UK's Flagship Health & Safety Event Has Successful Inaugural Year in London 4University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 2University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 3University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 4
... Pharmaceuticals, Inc. (Nasdaq: ALSE ), announced today that ... Altropane Parkinson,s or Essential Tremor (POET-2) Phase III ... the program was to acquire the set of Altropane images ... Phase III registration portion of the program. The Altropane ...
... Care approach designed to help improve medication adherence to ... 3 /PRNewswire/ -- A study ... ) found that nearly half of patients hospitalized for ... therapies, significantly increasing their risk for subsequent hospitalization within ...
Cached Medicine Technology:Alseres Pharmaceuticals Completes Enrollment in First Stage of the Altropane(R) POET-2 Phase III Program 2Alseres Pharmaceuticals Completes Enrollment in First Stage of the Altropane(R) POET-2 Phase III Program 3Alseres Pharmaceuticals Completes Enrollment in First Stage of the Altropane(R) POET-2 Phase III Program 4Alseres Pharmaceuticals Completes Enrollment in First Stage of the Altropane(R) POET-2 Phase III Program 5CVS Caremark Study Finds Non-Adherent Heart Failure Patients Almost Twice as Likely to be Re-Hospitalized Within a Year 2CVS Caremark Study Finds Non-Adherent Heart Failure Patients Almost Twice as Likely to be Re-Hospitalized Within a Year 3CVS Caremark Study Finds Non-Adherent Heart Failure Patients Almost Twice as Likely to be Re-Hospitalized Within a Year 4
(Date:7/11/2014)... Ticket Down is a reliable source for ... When it comes to the summer concert schedule, it just isn’t ... is one of the biggest names in country music and one ... out on his “That’s My Kind of Night” tour featuring Lee ... be making through the rest of the summer and into the ...
(Date:7/11/2014)... (PRWEB) July 11, 2014 According to ... & Application Market by Communication Technology (ZigBee, Z-Wave, Bluetooth, ... Electronics, Industrial, Automotive & Transportation, Agriculture) & Geography - ... value of Internet of Things market was worth $1029.5 ... Billion by 2020, at an estimated CAGR of 4.08% ...
(Date:7/11/2014)... Presently, disposable medical suppliers call for the biggest ... During the past two decades, the world market for ... 12.5% per year), primarily owing to the importance of ... the largest market for disposable medical supplies in the ... position is held by Europe with a 29% market ...
(Date:7/11/2014)... 2014) Obese and overweight firefighters are not ... providers, according to new research from The University ... , National guidelines state that health care professionals ... maintaining a healthy weight. Firefighters have high rates ... cause of line-of-duty deaths in firefighters. This study ...
(Date:7/11/2014)... to repair damage to the anterior cruciate ligament (ACL) -- ... could increase a young athlete,s risk for further injuries, researchers ... aged 8 to 16, who had ACL reconstruction surgery. Of ... their injury, 37 had surgery six to 12 weeks after, ... their injury. The youngsters who had surgery later had ...
Breaking Medicine News(10 mins):Health News:Luke Bryan Ticket Prices Slashed at Concord Pavilion 2Health News:Luke Bryan Ticket Prices Slashed at Concord Pavilion 3Health News:Internet of Things Technology & Application Market Worth $1423.09 Billion by 2020 – New Report by MarketsandMarkets 2Health News:Internet of Things Technology & Application Market Worth $1423.09 Billion by 2020 – New Report by MarketsandMarkets 3Health News:Internet of Things Technology & Application Market Worth $1423.09 Billion by 2020 – New Report by MarketsandMarkets 4Health News:Global Disposable Medical Supplies Market to See Robust Growth Through Next Decade, According to New TriMark Report Available at MarketPublishers.com 2Health News:Global Disposable Medical Supplies Market to See Robust Growth Through Next Decade, According to New TriMark Report Available at MarketPublishers.com 3Health News:Delaying Kid's Knee Surgery Could Be a Bad Play, Study Finds 2
... July 13, 2010 The decision regarding treatment following ... (DCIS) has long been an area of discussion and ... rates for DCIS remain low, the risk of local ... surgery include radiation therapy and hormone treatment. While ...
... Science Associates, the company that manages the U.S. ... Engineering Technologies, Inc. (BioSET) of Rockville, Maryland, have ... second-generation technology for designing synthetic peptides that are ... are designed to communicate growth signals to cells ...
... HealthDay Reporter , TUESDAY, July 13 (HealthDay News) -- ... decade ago that the blockbuster diabetes drug caused an increased ... to a report published Tuesday in The New York ... its competitor, Actos, the drug company, then known as SmithKline ...
... ARBOR, Mich.---Dostoyevsky and Tolstoy portrayed Russians as a brooding, ... to focus on dark feelings and memories more than ... finds that even though Russians tend to brood, they ... as a result. "Among Westerners, focusing on one,s ...
... health threats ranging from swine flu to bioterrorism to ... vast potential to protect the public. In a paper ... in Emerging Health Threats Journal , public health ... surveillance, detailing innovations on the horizon that may facilitate ...
... Children and young adults with Tourette syndrome can gain control ... suggests. But a specialist in the condition said the ... works. In the study, reported in the July/August ... , researchers used a video to teach 33 people aged ...
Cached Medicine News:Health News:Prediction tool helps estimate local recurrence in patients with noninvasive breast cancer 2Health News:Prediction tool helps estimate local recurrence in patients with noninvasive breast cancer 3Health News:Brookhaven Lab and BioSET Inc. patent improved growth factor technology 2Health News:Avandia Heart Risks Buried by Drug Company: Report 2Health News:Avandia Heart Risks Buried by Drug Company: Report 3Health News:Brooding Russians: Less distressed than Americans 2Health News:Researchers envision better disease surveillance to improve public health 2Health News:Can Self-Hypnosis Help Tourette Patients Control Tics? 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: